Ipamorelin is a synthetic pentapeptide in the growth hormone secretagogue class, a ghrelin receptor agonist that prompts the pituitary to release the body's own growth hormone rather than supplying hormone from outside. Novo Nordisk developed it in the late 1990s as NNC 26-0161 and studied it for conditions such as postoperative ileus before discontinuing commercial development, so it never reached approval as a marketed drug. The honest bottom line is a credible mechanism set against a thin human outcome record and an unsettled regulatory standing that is trending toward tighter restriction.
Ipamorelin is a selective ghrelin receptor agonist with no FDA approval, a documented short-term growth hormone effect, and a thin human evidence base for the body-composition and recovery claims commonly attached to it.
Ipamorelin is a five-amino-acid peptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, built to resist rapid breakdown and act as a focused signal to the pituitary. The published mechanism is well characterized: it binds the growth hormone secretagogue receptor (GHS-R1a) on somatotroph cells of the anterior pituitary and blunts somatostatin at the hypothalamus, producing a pulsatile release of stored growth hormone that mirrors the body's natural rhythm. What sets it apart in the literature is selectivity at typical doses, with cortisol, prolactin, and hunger reported as largely untouched.
The literature describes ipamorelin as a GHS-R1a agonist with a plasma half-life of roughly two hours, producing a transient, pulsatile growth hormone release rather than a continuous elevation.
The proximate, best-documented effect reported in the literature is a rise in circulating growth hormone followed by a downstream increase in insulin-like growth factor 1 (IGF-1), the hormone through which much of growth hormone's anabolic and repair signaling occurs. From that single mechanism flow the outcomes pursued by users: lean muscle retention, faster recovery, gradual body-composition shifts, and deeper slow-wave sleep, the last of which is biologically plausible given that natural growth hormone release peaks during deep sleep. The honest framing separates mechanism from proof, because most muscle, fat, recovery, and anti-aging claims extrapolate from growth hormone biology and user reports rather than resting on controlled human trials.
The only well-documented effect of ipamorelin is a rise in growth hormone and IGF-1, while the muscle, fat-loss, recovery, and anti-aging benefits attributed to it rest on mechanism and user reports rather than on robust controlled trials in healthy people.
No approved label exists for ipamorelin, so every dosing figure in circulation reflects off-label and research practice rather than an established standard of care. Published off-label practice describes doses in the range of roughly 200 to 300 micrograms per administration, given one to three times daily, delivered by subcutaneous injection because the peptide is not orally bioavailable and would be destroyed in the digestive tract. The literature also documents pairing with a growth-hormone-releasing-hormone analog such as CJC-1295, on the rationale that the two complementary pathways together produce a larger and more sustained pulse than either reaches alone.
There is no validated dosing standard for ipamorelin; reported off-label practice describes roughly 200 to 300 micrograms by subcutaneous injection one to three times daily, often timed before bed in a fasted state and frequently stacked with a GHRH analog such as CJC-1295.
The cautionary picture in the published record splits into the observed and the unknown. In short-term use the reported side effects are mild and local or transient, including injection-site irritation, headache, flushing, lightheadedness, and occasional water retention or tingling in the extremities, with little reported effect on cortisol and prolactin. The more serious concerns are theoretical and tied to elevated growth hormone and IGF-1, including the possibility of promoting growth of existing tumors, joint and soft-tissue effects, reduced insulin sensitivity, and unknown long-term consequences, layered on top of a product-quality risk from unregulated supply channels.
Short-term side effects reported for ipamorelin are mild and mostly local, but the serious concerns are unproven long-term risks tied to elevated growth hormone and IGF-1, including possible tumor promotion and reduced insulin sensitivity, compounded by contamination and mislabeling risk in unregulated supply.
Ipamorelin has never been approved by the US Food and Drug Administration for any indication; its commercial development was discontinued and it holds no marketed-drug status. Because it is not an approved drug, it occupies an ambiguous space, sold either labeled as a research chemical for laboratory use only and explicitly not for human consumption, or through compounding channels whose access has narrowed sharply after the FDA moved to restrict many peptides from being compounded. The practical reading of the record is that the research-chemical label functions as a disclaimer rather than a quality or safety designation.
| Dimension | Status |
|---|---|
| FDA approval | None for any indication; development discontinued |
| Compounding pathway | Substantially narrowed under FDA peptide restrictions |
| Research-chemical sale | Labeled laboratory use only, not for human consumption |
| Competitive sport | Prohibited at all times under WADA secretagogue ban |
| Individual purchase | Gray zone dependent on jurisdiction and marketing |
Ipamorelin has no FDA approval and no marketed-drug status, is banned in competitive sport under the World Anti-Doping Agency's prohibition on growth hormone secretagogues, and its overall regulatory standing is unsettled and trending toward tighter restriction rather than legitimization.
Secretagogues fall into two families that reach the same endpoint through different receptors, and ipamorelin's profile is clearest when mapped against its neighbors. It belongs to the ghrelin-receptor-agonist family alongside GHRP-6, GHRP-2, and hexarelin, while CJC-1295 and sermorelin act through the growth-hormone-releasing-hormone receptor. The distinction the published record treats as most important is against exogenous synthetic HGH, which delivers growth hormone directly and bypasses pituitary feedback, whereas ipamorelin prompts the body to release its own hormone in natural pulses still subject to normal regulation.
| Compound | Family / mechanism | Profile vs. ipamorelin |
|---|---|---|
| CJC-1295 | GHRH receptor, long-acting | Sustained elevation; complements ipamorelin's short pulse, hence common pairing |
| GHRP-6 / GHRP-2 | Ghrelin receptor agonists | Stimulate appetite and can raise cortisol and prolactin, effects ipamorelin largely avoids |
| Hexarelin | Ghrelin receptor agonist | Most potent but most prone to desensitization and raising cortisol and prolactin |
| Synthetic HGH | Exogenous growth hormone | Delivers hormone directly, higher and less physiological levels, greater suppression of natural output |
Within the secretagogue class ipamorelin is documented as the more selective, cleaner-profile option that trades peak potency for tolerability, and unlike exogenous synthetic HGH it works through the pituitary in natural pulses subject to normal feedback.
The clinical record is modest and largely dated to the original development era rather than to current popular use. Novo Nordisk created the compound in the 1990s and investigated it as a growth hormone secretagogue, with one notable line of study targeting postoperative ileus on the rationale that ghrelin-receptor activity could stimulate gut motility, but the program was discontinued for commercial and business reasons rather than a specific safety scandal. Early-phase human work confirmed it reliably and dose-dependently raised growth hormone with a favorable selectivity profile, which validates the pharmacology but does not substitute for large human outcome trials.
Ipamorelin is mechanistically well characterized with confirmed short-term pharmacology from its 1990s development, but there are essentially no large, long-term controlled trials in healthy adults for its present-day body-composition and anti-aging uses, so the confident claims around it outrun the published research.
The cost reality is a low per-vial price set against a high uncertainty cost. A single vial of typically five to ten milligrams of lyophilized powder commonly runs in the range of a few tens of dollars, with monthly cost depending on dose, frequency, and whether it is stacked with another peptide. Access splits along two channels with very different oversight, and independent testing of gray-market peptides repeatedly finds underdosed, contaminated, or mislabeled product, so the cheap price and the integrity of the material can diverge sharply.
A vial of ipamorelin commonly costs only a few tens of dollars and is never covered by insurance, but the genuine expense is the documented uncertainty about legality, oversight, and material integrity, since independent testing of gray-market peptides repeatedly finds underdosed, contaminated, or mislabeled product.
Educational use only. This article describes what the published scientific and clinical literature reports about Ipamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
